| Document |
Document Title |
|
WO/2021/052353A1 |
The present invention relates to the technical field of enzyme inhibitors, and relates in particular to a hydroxamic acid derivative, a preparation method therefor and an application thereof. The hydroxamic acid group in the hydroxamic a...
|
|
WO/2021/046640A1 |
The present disclosure relates to new cannabinoid derivatives and precursors and catalytic asymmetric processes for their preparation. The disclosure also relates to pharmaceutical compositions and pharmaceutical and analytical uses of t...
|
|
WO/2021/044430A1 |
The present invention relates to compounds, compositions and methods for treating fibrosis. In particular, compounds that inhibit or downregulate Sirtuin 1 (SIRT1) activity, which are particularly useful in the treatment of Idiopathic Pu...
|
|
WO/2021/007190A1 |
A process for preparing and purifying a compound of Formula (I) is provided; or a salt thereof, wherein the subscript m is an integer of from 0 to 3; each Ra is independently selected from the group consisting of (C3-C8)cycloalkyl, (C1-C...
|
|
WO/2021/005294A1 |
The present invention relates to a compound of the following formula (I): H-CO-N(OH)-CH2-CH(R1)-CO-NH-(CH2)n-CH(R2)-(CH2)m-CO-R3 (I) as well as a pharmaceutically acceptable salt and/or solvate thereof. The present invention also relates...
|
|
WO/2020/254558A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...
|
|
WO/2020/201089A1 |
The present invention relates to a complex comprising a transition metal cation (i); a ligand (ii) comprising at least one chelating group, preferably from 1 to 4 chelating groups, more preferred 2 or 3 chelating groups, wherein the chel...
|
|
WO/2020/198401A1 |
The disclosure provides a method of treating a malignant rhabdoid tumor in a subject in need thereof including administering to the subject a therapeutically-effective amount of (S)-N-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-c...
|
|
WO/2020/193431A1 |
The present invention relates to novel inhibitors of histone deacetylase 10 (HDAC10), novel pharmaceutical compositions comprising such inhibitors, and to novel methods of treating diseases, such as cancer, autoimmune disorders or neurod...
|
|
WO/2020/127924A1 |
The invention relates to a process for the preparation of Voxelotor, or a salt or solvate thereof, which comprises the use of a compound of formula (I) or (I'), or a salt or solvate thereof.
|
|
WO/2020/129900A1 |
The purpose of the present invention is to provide a method for industrially and efficiently producing a C-arylhydroxy glycoxide derivative at low cost. The present invention provides a method for producing a C-arylhydroxy glucoxide deri...
|
|
WO/2020/064818A1 |
Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process.
|
|
WO/2020/061367A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2020/061340A1 |
Included within the scope of the invention are methods of preparing a shelf-stable Formulation comprising mixing a solvent, at least one of a surfactant, a fabric conditioner, detersive agent (detergent), emulsifier, humectant, a coloran...
|
|
WO/2020/002238A1 |
The present invention provides compounds of formula (I) for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
|
|
WO/2019/219938A1 |
The invention discloses Fmoc protected (2S)-2-amino-8-[(1,1- dimethylethoxy)amino]-8-oxo-octanoic acid, (S)-2-amino-8- oxononanoic acid and (S)-2-amino-8-oxodecanoic acid for use in peptide synthesis, such as solid phase synthesis, as we...
|
|
WO/2019/218445A1 |
Disclosed is a method for synthesizing a urease inhibitor acetohydroxamic acid. The method comprises: reacting hydroxylamine hydrochloride with ethyl acetate in an alkaline solvent system, and after the completion of the reaction, extrac...
|
|
WO/2019/210742A1 |
The present invention relates to a novel acrylic ketone oxime ester compound, a preparation method therefor, and a composition thereof. The acrylic ketone oxime ester compound of the present invention can initiate the occurrence of a pol...
|
|
WO/2019/196780A1 |
The present invention relates to the field of pharmaceutical chemistry. Disclosed are a novel indoleamine-2,3-dioxygenase (IDO) inhibitor, a preparation method therefor, and a use thereof. The IDO inhibitor in the present invention has a...
|
|
WO/2019/178677A1 |
The present disclosure relates to the targeted delivery of defined active agents and/or immunomodulatory agents to lymph nodes or lipoid cells in a lymphatic tissue. More particularly, the invention provides methods for targeted delivery...
|
|
WO/2019/161705A1 |
Disclosed is a new method for synthesizing 1,6-(p-amidinophenyl)hexyl diether, comprising the steps of: (1) preparing 1,6-(p-cyanophenyl)hexyl diether by reacting p-cyanophenol with 1,6-dibromohexane; (2) reacting the 1,6-(p-cyanophenyl)...
|
|
WO/2019/141740A1 |
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein Q, X, Z, R2 and R3 are as described herein. The inventions further relates to compositions comprising said compounds, to meth...
|
|
WO/2019/139921A1 |
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
|
|
WO/2019/053382A1 |
The invention relates to the use of alkoxy-amine-borane complexes for storing hydrogen.
|
|
WO/2019/051222A1 |
The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): --̅-̅-̅ is a single or double bond; n is an integer of 0 or 1; A is -CH2-, -CH(OH)-, or - C(O)-; G is C or N; X is -CH2-, O, or -C(O)-; Y is alkyl...
|
|
WO/2019/025426A1 |
The invention relates to hydrazide compounds and their use in medicine, particularly in treating and /or preventing infections caused by a fungus.
|
|
WO/2018/234139A1 |
2-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]aryloxy](thio)a
cetamides for combating phytopathogenic fungi The present invention relates the compounds of the formula I and their N-oxides and agriculturally acceptable salts thereof, and t...
|
|
WO/2018/191360A1 |
Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/148476A1 |
Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.
|
|
WO/2018/144800A1 |
Provided are compositions, methods and devices for reducing scarring during healing of a tissue wound. The compositions and methods involve use of sphingosine-1 -phosphate (SIP), and/or an expression vector that encodes sphingosine kinas...
|
|
WO/2018/115421A1 |
The present invention discloses compounds of formula (I) that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
|
|
WO/2018/098401A1 |
The present invention describes compositions, including pharmaceutical compositions, comprising an agent that binds members of the TNFRSF and a benzamide compound and methods for use thereof, for example in the treatment of cancer. In so...
|
|
WO/2018/089651A1 |
The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.
|
|
WO/2018/081858A1 |
The present invention relates to new desferrioxamine B analogues that are useful for iron-chelation therapy, to their preparation including intermediates, and to compositions including the compounds. The present invention also relates to...
|
|
WO/2018/060354A1 |
The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them, wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and ot...
|
|
WO/2018/053080A1 |
Acute kidney injury (AKI) is often associated with damage to remote organs, such as lungs or heart. AKI induces kidney tubular necrosis as well as NETosis, programmed neutrophil death leading to neutrophil extracellular traps (NETs). His...
|
|
WO/2018/015595A3 |
The present invention relates to a family of compounds which are effective against parasites of the genus Leishmania, preferably caused by L. infantum, L. major or L. tropica, and which have low toxicity, even at high doses of the compou...
|
|
WO/2018/011811A3 |
A pharmaceutical composition and a method of treating, reducing or preventing vascular, cardiovascular arterial or valve calcification in a subject in need comprising administering to the subject an effective amount of an agent that prev...
|
|
WO/2017/195216A4 |
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and...
|
|
WO/2018/015292A1 |
The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cance...
|
|
WO/2018/015493A1 |
A metal complex has the general formula (I), in which: R-Z is a HDAC inhibitor in which Z a terminal hydroxamate group; M is a redox active metal; n+ is the positive charge on the complex cation; Bn- is a balancing counterion; Z binds to...
|
|
WO/2017/217553A1 |
[Problem] To provide a novel agricultural chemical, and particularly an herbicide. [Solution] An oxime compound represented by formula (1) and an herbicide containing the same. (In formula (1): B represents B-1 or the like; Q represents ...
|
|
WO/2017/204144A1 |
Provided is a method for amidating a hydroxy ester compound at a high chemical selectivity. The amidation reaction method for a hydroxy ester compound comprises, in the presence of a catalyst containing a compound of a transition metal o...
|
|
WO/2017/118822A3 |
The present invention relates to the design of new molecules, referred to as "multi-target" molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDAC) and as inhibitors of tubulin polymerisation...
|
|
WO/2017/201441A1 |
The present invention provides a method of imaging a subject's lung which comprises contacting the subject's lung with a matrix metalloproteinase inhibitor labeled with a radioisotope under conditions such that the inhibitor binds to mat...
|
|
WO/2017/199028A1 |
A method of preparing an active agent or a salt thereof from a prodrug first compound (1) comprising a propargyl group connected to an oxygen that is directly or indirectly connected to the active agent is provided, wherein the bond betw...
|
|
WO/2017/195216A1 |
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and...
|
|
WO/2017/181811A1 |
Disclosed are an opctahydroanthracene compound as represented by formula (I) or (II), a preparation method for same, and uses of same, which provides great therapeutic effects for tumors and neurodegenerative diseases and is prepared mai...
|
|
WO/2017/182433A1 |
The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin β and/or α, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially su...
|
